Selected article for: "animal model and decreased activity"
Author: Konduri, Kameswari S.; Pattisapu, Ram; Pattisapu, Jogi; Konduri, Girija G.; Zwetchkenbaum, John; Roy, Bidhan; Barman, Monalisa; Frazier, Adria; Hurst, Brett L.; Düzgüneş, Nejat
Title: ProLungâ„¢-budesonide Inhibits SARS-CoV-2 Replication and Reduces Lung Inflammation
  • Cord-id: wr71a0ll
  • Document date: 2021_5_5
    • ID: wr71a0ll
    Snippet: Background Inhaled budesonide benefits patients with COVID-19. ProLung™-budesonide enables the sustained, low dose administration of budesonide within a delivery vehicle similar to lung surfactant. ProLung™-budesonide may offer anti-inflammatory and protective effects to the lung in COVID-19, yet it’s effect on SARS-CoV-2 replication is unknown. Objective To determine the efficacy of ProLung™-budesonide against SARS-CoV-2 infection in vitro, evaluate its ability to decrease inflammation,
    Document: Background Inhaled budesonide benefits patients with COVID-19. ProLung™-budesonide enables the sustained, low dose administration of budesonide within a delivery vehicle similar to lung surfactant. ProLung™-budesonide may offer anti-inflammatory and protective effects to the lung in COVID-19, yet it’s effect on SARS-CoV-2 replication is unknown. Objective To determine the efficacy of ProLung™-budesonide against SARS-CoV-2 infection in vitro, evaluate its ability to decrease inflammation, and airway hyperresponsiveness in an animal model of lung inflammation. Methods SARS-CoV-2-infected Vero 76 cells were treated with ProLung™-budesonide ([0.03– 100 μg/ml]) for 3 days, and virus yield in the supernatant was measured. Ovalbumin-sensitized C57BL/6 mice received aerosolized (a) ProLung™-budesonide weekly, (b) only budesonide, either daily or weekly, or (c) weekly empty ProLung™-carrier (without budesonide). All treatment groups were compared to sensitized untreated, or normal mice using histopathologic examination, electron microscopy (EM), airway hyperresponsiveness (AHR) to Methacholine (Mch) challenge, and eosinophil peroxidase activity (EPO) measurements in bronchioalveolar lavage (BAL). Results ProLung™-budesonide showed significant inhibition on viral replication of SARS-CoV-2-infected cells with the selectivity index (SI) value > 24. Weekly ProLung™-budesonide and daily budesonide therapy significantly decreased lung inflammation and EPO in BAL. ProLung™-budesonide localized in type II pneumocytes, and was the only group to significantly decrease AHR, and EPO in BAL with Mch challenge Conclusions ProLung™-budesonide significantly inhibited viral replication in SARS-CoV-2 infected cells. It localized into type II pneumocytes, decreased lung inflammation, AHR and EPO activity with Mch challenge. This novel drug formulation may offer a potential inhalational treatment for COVID-19.

    Search related documents:
    Co phrase search for related documents
    • absence presence and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • absence presence and lung damage: 1, 2
    • absence presence and lung histopathology: 1
    • absence presence and lung inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • active drug and acute ards respiratory distress syndrome: 1
    • active drug and lung damage: 1
    • active drug and lung inflammation: 1
    • activity analysis and acute ards respiratory distress syndrome: 1, 2
    • activity analysis and lung histopathology: 1, 2
    • activity analysis and lung inflammation: 1
    • activity analysis and lung lavage: 1, 2
    • acute ards respiratory distress syndrome and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lung histopathology: 1, 2, 3, 4, 5, 6, 7
    • acute ards respiratory distress syndrome and lung inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lung inflammation critical role: 1
    • acute ards respiratory distress syndrome and lung inflammation critical role play: 1
    • acute ards respiratory distress syndrome and lung inflammation lead: 1
    • acute ards respiratory distress syndrome and lung inflammation reduce: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and lung lavage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17